Comparative Pharmacology
Head-to-head clinical analysis: TRIVARIS versus VERELAN PM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIVARIS versus VERELAN PM.
TRIVARIS vs VERELAN PM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
Verapamil is a calcium channel blocker that inhibits the influx of calcium ions across the cardiac and vascular smooth muscle cells, thereby reducing myocardial contractility, sinoatrial and atrioventricular node conduction, and vascular tone.
TRIVARIS 10 mg orally once daily, with or without food.
Verelan PM (verapamil hydrochloride) is an extended-release oral capsule administered once daily at bedtime. Typical adult dose for hypertension is 200 mg to 400 mg once daily at bedtime. Initial dose is 200 mg, titrated upward as needed. Maximum recommended dose is 400 mg daily.
None Documented
None Documented
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Terminal elimination half-life 7.2 ± 1.5 hours after oral administration, prolonged in hepatic impairment (up to 14-16 hours) and elderly; steady-state achieved after 3-4 days.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Primarily hepatic metabolism (>95%), with 3-4% excreted unchanged in urine; biliary/fecal excretion accounts for <1% of unchanged drug.
Category C
Category C
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination
Calcium Channel Blocker